source
- BlossomHill and Latigo close IPO week with $496 million raisedBlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week. Latigo, a company developing non‑opioid pain treatments, also went public at the same time. To…
- FDA outlines inspection overhaul, proposes IND reforms, and greenlights a disputed cancer therapyFDA officials announced a plan to restructure the agency’s inspectional operations, aiming to make inspections more efficient and focused. The proposed changes include consolidating regional office…